These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34219653)

  • 1. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data.
    Laydon DJ; Dorigatti I; Hinsley WR; Nedjati-Gilani G; Coudeville L; Ferguson NM
    Elife; 2021 Jul; 10():. PubMed ID: 34219653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
    DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
    Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
    Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
    N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
    Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
    Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
    Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
    Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
    Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
    Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
    Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
    Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
    Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
    Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
    Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
    Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
    Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.